. 2012 Oct 19;2(10):e95. doi: 10.1038/bcj.2012.30

resistant to imatinib^{19, 20, 35}.

	Chronic-phase CML²⁰ (n=186)		Accelerated-phase CML¹⁹(n=107)		Myeloid blast crisis³⁵(n=74)		Lymphoid blast crisis³⁵ (n=42)
	All gradesa	Grade 3/4	All gradesa	Grade 3/4	All gradesa	Grade 3/4	All gradesa	Grade 3/4
Nonhematologic
Abdominal pain	NR	NR	11	0	NR	NR	NR	NR
Anorexia	NR	NR	13	1	11	1	5	5
Arthralgia	NR	NR	10	0	11	3	5	0
Asthenia	20	2	19	4	15	3	10	2
Diarrhea	30	2	50	6	36	8	31	0
Dizziness	NR	NR	11	0	NR	NR	NR	NR
Dyspnea	27	3	16	4	18	7	12	0
Epistaxis	NR	NR	11	0	12	1	2	0
Fatigue	28	1	23	4	12	1	29	5
Febrile neutropenia	NR	NR	NR	NR	4	4	14	12
Gastrointestinal hemorrhage	NR	NR	11	7	12	8	0	0
Headache	34	1	28	1	8	0	14	2
Myalgia	NR	NR	10	1	NR	NR	NR	NR
Nausea	19	1	22	0	16	4	24	0
Pain in extremity	NR	NR	14	0	NR	NR	NR	NR
Peripheral edema	18	0	22	0	19	0	12	0
Pleural effusion	19	3	23	3	28	14	14	2
Pyrexia	NR	NR	23	4	16	5	19	2
Rash	22	<1	15	1	12	0	17	5
Vomiting	NR	NR	11	0	16	1	10	2

Hematologic
Leukocytopenia	NR	25	NR	61	NR	64	NR	69
Neutropenia	NR	49	NR	82	NR	82	NR	79
Thrombocytopenia	NR	47	NR	76	NR	84	NR	88
Anemia	NR	22	NR	69	NR	68	NR	52

Abbreviations: AE, adverse event; CML, chronic myeloid leukemia; NR, not reported.

All-grade AEs reported when frequency was >10% for any AE.

Table 2. Percentage of common nonhematologic AEs (all grades and grade 3/4) and hematologic abnormalities (grade 3/4) at 8 months with dasatinib in patients intolerant/resistant to imatinib19, 20, 35.